About Our Research

Camidanlumab tesirine

ASH 2020
Poster:

Combination of camidanlumab tesirine, a CD25 targeted ADC, with gemcitabine elicits synergistic anti tumor activity in preclinical tumor models | View

ASH 2020
Presentation:

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma | View

ASH 2020
Poster:

Pharmacokinetic and Pharmacodynamic Correlates From the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma | View

ESMO 2020
Poster:

First-in-Human Study of Camidanlumab Tesirine (ADCT-301, Cami), an anti-CD25 Targeted Therapy in Patients with Advanced Solid Tumors: Pharmacokinetics (PK) and Biomarker Evaluation | View

ICML 2019
Presentation:

Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT-301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) | View

ICML 2019
Poster:

The anti-CD25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines | View

ASH 2018
Presentation:

Phase 1 Study of ADCT-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma | View

SITC 2018
Poster:

A CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor | View

ASH 2017
Poster:

Results from an Ongoing Phase 1 Study Indicate ADCT-301 (Camidanlumab Tesirine) Is Well Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia | View

ADCT-602

ASH 2020
Poster:

Analysis of ADCT-602 pre-clinical activity in B-cell lymphoma models and identification of potential biomarkers for its activity | View

ASH 2016
Poster:

ADCT-602 (hLL2-cys-PBD), a new site-specifically conjugated, pyrrolobenzodiazepine (PBD) dimer-based antibody drug conjugate (ADC) targeting CD22-expressing B-cell | View

AACR 2015
Poster:

Pre-clinical Activity of hLL2-PBD, a Novel Anti-CD22 Antibody-Pyrrolobenzodiazepine (PBD) Conjugate in Models of Non-Hodgkin Lymphoma | View

Mipasetamab uzoptirine (ADCT-601)

ESMO 2019
Poster:

A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors | View

AACR 2018
Poster:

Pre-clinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors | View

ADCT-701

AACR 2018
Poster:

ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors | View